Vera Therapeutics Inc. Class A Common Stock (VERA)

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluat…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

361

Website

veratx.com/

Fundamentals

1-day range

$33.34$34.42

Market cap

$2.31B

P/E (trailing)

—

P/E (forward)

-7.75

EPS (trailing)

$-5.54

Dividend yield

—

Beta

0.99

Avg. volume

2.09M

Forecasts

14 analyst ratings

Vera Therapeutics Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• VERA

  Vera Therapeutics Inc. Class A Common Stock

  $34.19

  ▼ 1.18%
  Market cap $2.31BP/E —
  $21.2$56.05
• PGEN

  Precigen Inc. Common Stock

  $6.94

  ▼ 3.55%
  Market cap $2.36BP/E —
  $2.99$7.72
• KLRA

  Kailera Therapeutics Inc. Common Stock

  $16.26

  ▼ 12.25%
  Market cap $2.24BP/E —
  $16.19$28.23
• NKTR

  Nektar Therapeutics Common Stock

  $72.57

  ▼ 2.66%
  Market cap $2.38BP/E —
  $27.87$109
• RARE

  Ultragenyx Pharmaceutical Inc. Common Stock

  $25.62

  ▼ 2.46%
  Market cap $2.46BP/E —
  $18.29$39.89
• NUVB

  Nuvation Bio Inc. Class A Common Stock

  $6.67

  ▼ 4.65%
  Market cap $2.14BP/E —
  $2.87$9.75
• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.13BP/E —
  $14.94$47.65

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy
  SeekingAlpha · 8/17/2026
• Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target
  benzinga · 8/17/2026
• Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target
  Benzinga · 8/17/2026
• Heartflow, Eton Pharmaceuticals, Nu Holdings And Other Big Stocks Moving Higher On Friday
  Benzinga · 8/14/2026
• HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90
  Benzinga · 8/12/2026
• Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34
  Benzinga · 8/11/2026
• Vera Therapeutics Q2 EPS $(1.52) Beats $(1.61) Estimate
  Benzinga · 8/10/2026

• Boman Nancy Lee · August 3, 2026 · Grant

  63.0K
• Boman Nancy Lee · August 3, 2026 · Grant

  45.0K
• Fordyce Marshall · July 7, 2026 · Sale

  2.2K @ $43.59
• Fordyce Marshall · July 7, 2026 · Sale

  10.5K @ $42.86
• Fordyce Marshall · July 7, 2026 · Sale

  32.5K @ $42.07
• Fordyce Marshall · July 7, 2026 · Sale

  1.0K @ $40.78
• Fordyce Marshall · July 7, 2026 · Option Exercise

  46.3K @ $2.9
• Fordyce Marshall · June 23, 2026 · Sale

  88 @ $38.43
• Fordyce Marshall · June 23, 2026 · Sale

  18.4K @ $37.93
• Fordyce Marshall · June 23, 2026 · Option Exercise

  18.5K @ $2.9
• Hall Kimball · May 21, 2026 · Grant

  17.1K
• Oliger Christy J. · May 21, 2026 · Grant

  17.1K
• Cheng Andrew · May 21, 2026 · Grant

  17.1K
• Scott W. Morrison · May 21, 2026 · Grant

  17.1K
• Meyers James R · May 21, 2026 · Grant

  17.1K

Institutional Ownership

March 31, 2026

Total shares held

71.86M

Total value held

$2.71B

Institutional holders

222